Cellomatics Biosci

In our latest meet the team blog we discuss Klaudia's experience at university and working for the NHS as well as the projects she has worked on during her time at Cellomatics. Read more here: bit.ly/4rN6HG2

We are thrilled to announce that Cellomatics CEO and Founder Shailendra Singh has been shortlisted for the East Midlands Boardroom Awards 2026, within the category of Scale-up Entrepreneur of the Year. Read more about the shortlist here bit.ly/401EkYG

Today is Rheumatoid Arthritis Awareness Day, a vital initiative observed annually on 2 February aimed at spreading awareness about rheumatoid arthritis, an autoimmune disease that affects millions of people worldwide. Read more here: bit.ly/4bPoszV

In our latest meet the team blog we discuss Thomas Cox’s scientific journey and the work he undertakes at Cellomatics since joining in January 2024 as an Associate Scientist. Read our blog to learn more: bit.ly/4jRf14D

Merry Christmas and a joyous New Year from the Cellomatics team! We hope you enjoy the festive season🌟

With 2025 coming to an end, we sat down with CEO and founder of Cellomatics Biosciences, Dr Shailendra Singh, to get his thoughts on the previous twelve months and his view of where he thinks Cellomatics will be in 2026. Find out more: bit.ly/48DIyLo

Our offices will be closed from 25th December 2025 to 1st January 2026. We will resume normal operations on 2nd January 2026. We appreciate your understanding and wish you a happy and healthy festive season.

Excited to share my article on how organoid and 3D models are redefining drug testing @CBioscien linkedin.com/pulse/organoid… #Organoids #DrugDiscovery #PreclinicalResearch #HumanRelevantModels #3DCellCulture

🔬 Exciting growth for @CBioscien 🚀 With support from @DerbyUni’s Invest to Grow, @CBioscien has expanded its lab capabilities - boosting productivity, creating jobs & driving biomedical innovation in oncology, immunology & more. 🚀 Find out more👉 ow.ly/fRV150XfpMO

We’re thrilled to welcome Cellomatics Biosciences (@CBioscien) to the 2025 Go Global Awards! 🌍 Your participation highlights excellence, innovation, and global collaboration. Thank you for joining this platform celebrating leadership and success! #GoGlobalAwards2025

We’re thrilled to welcome Cellomatics Biosciences (@CBioscien) to the 2025 Go Global Awards! 🌍 Your participation highlights excellence, innovation, and global collaboration. Thank you for joining this platform celebrating leadership and success! #GoGlobalAwards2025

Cellomatics has been named as a finalist for the prestigious Bioscience Innovator of the Year award at the Go Global Awards 2025! Visit our website to find out more: bit.ly/47KPx3B

We're thrilled to announce that Cellomatics has been nominated for the prestigious Go Global Awards 2025, which will be held in November 18–19, at One Great George Street, Westminster, London. Find out more here: bit.ly/47KPx3B

Cellomatics offer customisable, high-throughput Caco-2 IBD models that can deliver physiologically relevant insights into Crohn’s and colitis, with flexible readouts including cytokine release, gene expression, and barrier integrity. Find out more: bit.ly/3UO4H1O

Our T-cell assays provide powerful insights into immune function—from polarisation and proliferation to killing activity—using flexible readouts including cell counts, cytokine release, multiplex analysis, and imaging. Learn more: bit.ly/49v1Wrc

Our latest Science Communication piece is live🧑‍🔬 Visit out website for an in depth look at the molecular capabilities we have at Cellomatics and how you may be able to utilise them for your projects: bit.ly/4mm8Tku

September is Blood Cancer Awareness Month and 15 September marks World Lymphoma Awareness Day. Learn more about blood cancer and the various in vitro assays we have developed at Cellomatics to support drug discovery projects against diseases like these: bit.ly/46gEjmp

Our NETosis Assay delivers high-throughput, customisable analysis using freshly isolated immune cells from healthy and diseased donors. With flexible readouts you gain powerful insights into immune mechanisms and drug effects. Learn more here: bit.ly/3HORl2r

Our Parkinson’s disease neuroinflammation model uses differentiated SH-SY5Y neurons treated with 6-OHDA, enabling high-throughput, reproducible insights with multiple readout options including ELISA, qPCR, and imaging. Find out more: bit.ly/2YPuY6m